Delivery Order 75N91019D00024-75N91026F00026

The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 28, 2026, with a ceiling value of $1,683,296 for integrated DMPK and toxicology profiling of NCATS/TDB medicinal chemistry lead candidates. The order is cost-plus-fixed-fee and reaches ultimate completion on September 27, 2031.

Place of performance is Frederick, MD 21702. Leidos Biomedical Research operates as an FFRDC contractor delivering biomedical research and facilities support to the National Institutes of Health. The company's biomedical research capability portfolio spans research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing including monoclonal antibodies, gene therapy vector manufacturing, and vaccine platform development. Leidos Biomedical Research maintains a workforce of approximately 1,830 FTEs and engages a network of subcontractors including Abbott Molecular Inc., Tecan U.S. Inc., Bio-Rad Laboratories, and academic partners such as Stanford University and the University of Pittsburgh for specialized research activities.